1. Home
  2. IOVA vs GETY Comparison

IOVA vs GETY Comparison

Compare IOVA & GETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • GETY
  • Stock Information
  • Founded
  • IOVA 2007
  • GETY 1995
  • Country
  • IOVA United States
  • GETY United States
  • Employees
  • IOVA N/A
  • GETY N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • GETY Industrial Machinery/Components
  • Sector
  • IOVA Health Care
  • GETY Industrials
  • Exchange
  • IOVA Nasdaq
  • GETY Nasdaq
  • Market Cap
  • IOVA 771.4M
  • GETY 723.5M
  • IPO Year
  • IOVA N/A
  • GETY N/A
  • Fundamental
  • Price
  • IOVA $1.98
  • GETY $1.84
  • Analyst Decision
  • IOVA Buy
  • GETY Hold
  • Analyst Count
  • IOVA 10
  • GETY 5
  • Target Price
  • IOVA $12.22
  • GETY $4.35
  • AVG Volume (30 Days)
  • IOVA 11.2M
  • GETY 903.2K
  • Earning Date
  • IOVA 08-07-2025
  • GETY 08-08-2025
  • Dividend Yield
  • IOVA N/A
  • GETY N/A
  • EPS Growth
  • IOVA N/A
  • GETY N/A
  • EPS
  • IOVA N/A
  • GETY N/A
  • Revenue
  • IOVA $212,679,000.00
  • GETY $941,086,000.00
  • Revenue This Year
  • IOVA $86.62
  • GETY $2.71
  • Revenue Next Year
  • IOVA $69.95
  • GETY $2.74
  • P/E Ratio
  • IOVA N/A
  • GETY N/A
  • Revenue Growth
  • IOVA 11070.12
  • GETY 4.20
  • 52 Week Low
  • IOVA $1.64
  • GETY $1.25
  • 52 Week High
  • IOVA $12.51
  • GETY $4.49
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 43.44
  • GETY 52.72
  • Support Level
  • IOVA $1.95
  • GETY $1.60
  • Resistance Level
  • IOVA $2.47
  • GETY $1.85
  • Average True Range (ATR)
  • IOVA 0.15
  • GETY 0.10
  • MACD
  • IOVA 0.05
  • GETY 0.01
  • Stochastic Oscillator
  • IOVA 35.53
  • GETY 45.92

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About GETY Getty Images Holdings Inc.

Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.

Share on Social Networks: